VIM and lung adenocarcinoma: Although Maeda et al. reported that patients with stage I lung adenocarcinoma lacking the expression of either MYH9 or vimentin show a favorable outcome without postoperative adjuvant chemotherapy [14], the present study revealed that MYH9 expression is an independent prognostic factor for survival in patients with resected NSCLCs including pathological stage I-III and lung squamous cell carcinoma.